Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14888163 | 1.00 | NCF1 (0.37) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14386288 | 1.00 | NCF1 (0.37) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13354978 | 1.00 | NCF1 (0.37) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1355855 | 1.00 | NCF1 (0.37) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL14311930 | 0.98 | NCF1 (0.35) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23865787 | 0.83 | NCF1 (0.37) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18968298 | 0.83 | NCF1 (0.37) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18968114 | 0.83 | NCF1 (0.37) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18968300 | 0.83 | NCF1 (0.37) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18968080 | 0.83 | NCF1 (0.37) | NCF1MRGPRX2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367800-B9 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | IPHARMA H K LTD (HK) | 2021-10-20 | — | — | EP | disclosed |
| EP-2367800-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INT (DE) | 2018-02-28 | — | — | EP | disclosed |
| WO-2018013676-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
| US-9676762-B2 | Pyrimidine compounds containing seven-membered fused ring systems | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20160362404-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20150376141-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20140371205-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| US-8846689-B2 | Substituted pyrimidines for the treatment of diseases such as cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371205-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | TYMP, HPRT1, TYMS | NCF1 1315/4885MRGPRX2 1152/4885SLC6A2 1588/4885 |
| US-20160362404-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | NCF1 859/4885MRGPRX2 64/4885SLC6A2 2398/4885 |
| US-20150376141-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | NCF1 449/4885MRGPRX2 105/4885SLC6A2 2375/4885 |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | TYMP, HPRT1, TYMS | NCF1 1315/4885MRGPRX2 1152/4885SLC6A2 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.